SCHEMBL7189202

SCHEMBL7189202

CCOc1ccc(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(C)c1.[LiH]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.38
TP53 P04637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
KCNK3 O14649 1/20 0.37
KCNK9 Q9NPC2 1/20 0.37
PDK2 Q15119 2/20 0.37
MAOB P27338 2/20 0.37
MAOA P21397 1/20 0.37
TAAR1 Q96RJ0 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186968 0.91 CYP2D6 (0.41) PDK2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7182421 0.91 KMT2A (0.40) KMT2AHPGDPDK2MAOBMAOA
SCHEMBL7188240 0.90 FFAR1 (0.39) KMT2AKDM4EHPGDTAAR1CYP1A2
SCHEMBL7182314 0.89 THRA (0.44) PDK2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7184698 0.88 KDM4E (0.42) KMT2AKDM4EHPGDTP53RXFP1
SCHEMBL7182716 0.88 THRA (0.46) PDK2CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7182639 0.88 PDK2 (0.40) HPGDPDK2MAOBMAOACYP1A2
SCHEMBL7181098 0.88 CYP1A2 (0.39) KDM4EHPGDMAOBMAOACYP1A2
SCHEMBL7180390 0.87 MAOB (0.40) KMT2AMAOBMAPTSMN1; SMN2NPSR1
SCHEMBL7177524 0.87 MRGPRX4 (0.45) MAOBMAPTL3MBTL1RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885KDM4E 3226/4885HPGD 3983/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885KDM4E 2651/4885HPGD 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.